Bombay (Maharashtra) [India]April 23 (ANI/PNN): Mumbai-based Inventys Research Company Pvt Ltd (“Inventys”https://www.devdiscourse.com/”the Company”) has confirmed the closing of a private placement round of 255 INR crore (USD 34 Mn). Arpit Khandelwal, managing partner of Plutus Wealth Management LLP, has committed INR 225 crore of primary infusion to the company, while India Inflection Opportunity Fund, managed by Pantomath Capital Management Pvt Ltd, is taking over the secondary round offered by some existing shareholders of the society. Pantomath Capital Advisors Private Limited acted as sole investment banker for the transaction. Inventys is a research-driven specialty chemicals manufacturer focused on custom synthesis and manufacturing (CSM). The company has a diverse product portfolio comprising advanced intermediates and actives used in plant protection/pharmaceutical applications as well as other specialty segments. Inventys is an essential member of several global supply chains with the particularity of generating a significant share of the revenues, Inventys being the ONLY manufacturer in the world of these chemicals. Behaving responsibly towards Mother Earth, the society we live in and the Inventys team – is the hallmark of the Inventys culture of safety, reliability and dependability.
Inventys has developed in-house capabilities for the development and manufacture of specialty chemicals requiring complex chemistries and materials, supported by 5 (five) state-of-the-art production blocks and R&D facilities located near Nagpur spread over 7 acres of ground. Factories are fully integrated backwards to widely available intermediaries, mitigating dependence on China. The Company has acquired over 17 acres of additional land that can accommodate 30 additional production blocks. Incorporated in 2005, Inventys was founded by Dr. Deepak Birewar, a very talented and wealthy experienced scientist with previous stints in global corporations such as DuPont. A chemical engineer by profession, Dr. Deepak Birewar has 12 years of professional experience in the United States and 18 years in India. Dr. Deepak Birewar was listed in Marquis Who’s Who in Science & Engineering (1994). BTech from IIT Bombay, Dr. Deepak Birewar holds a PhD in Chemical Engineering from Carnegie Mellon University, USA. Mr. Rushikesh Birewar joined Inventys in 2016 and focuses on R&D and new product development initiatives at Inventys. Rushikesh Birewar holds a dual degree in Chemical Engineering and Chemistry from the University of Wisconsin (Madison), USA. Inventys Board is comprised of industry veterans i.e. Umesh Kamat, BTech + MTech from IIT Bombay – having over 28 years of experience in Instrumentation, Control and Automation Systems as well as Satish Sohoni having more than 40 years of experience in the chemical industry.
Dr. Deepak Birewar, CMD of Inventys, said: “Inventys is committed to solving complex chemistries with made-in-India solutions for global markets. Research, innovation and a transparent work culture based on value are the hallmark of Inventys. leading national platform with world-class systems serving global markets. We welcome our investors and firmly believe that all stakeholders should be proud of Inventys. “We are looking at organic and inorganic growth. We are in preliminary discussions with a few global industrial companies for a strategic combination with Inventys. We are working on a mega expansion plan and releasing our private placement round, we are planning to prepare our trajectory of growth,” added Dr. Deepak Birewar.
With the arrival of Arpit Khandelwal, Inventys would be exposed to global markets, backed by the desired financial acumen. Khandelwal invests and backs businesses in India and around the world and is known for its picks. Speaking about his investments in Inventys, Arpit Khandelwal said: “Complex chemistries, especially in the CSM space, with established criticalities in the value chain of global industry players, are highly sought after by companies around the world. entire. These companies possess extremely high barriers to trade and command. We believe Inventys is well positioned to leverage its R&D and innovation capabilities combined with its superior engineering skills. We are excited to be part of Inventys’ long-term growth journey.
Making its first investment, India Inflection Opportunity Fund has taken over the secondary round offered by some existing shareholders of the Company. Speaking on the occasion, Madhu Lunawat, Fund Manager of India Inflection Opportunity Fund, “We were impressed with the depth, speed and execution capabilities of the Inventys team. to a company like Inventys, which is run by extremely professional people and highly skilled promoters with long-standing flawless business relationships with global giants.Representing a true “made in India and designed for the world” solution for global markets, replacing imports and favoring exports, Inventys scores optimally in our impactful inflection opportunity fund metrics.”
Inventys caters to large innovative global customers of multinationals in the crop protection/pharmaceutical industries and has long-term business relationships with global giants. Managing highly complex, multi-step synthesis supported by world-class R&D and advanced flow chemistry process engineering, the company has extremely high trade barriers to entry and exit. This story is provided by PNN. ANI will not be responsible for the content of this article. (ANI/PNN)
(This story has not been edited by the Devdiscourse team and is auto-generated from a syndicated feed.)